GRAIL’s Galleri received favorable FDA advisory committee support: unanimous on safety, six to four on effectiveness and seven to two with one abstention on benefits outweighing risks. GRAIL expects an FDA decision by early first quarter of 2027.
GRAL · GRAIL, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
GRAIL expects an FDA decision on Gallery by early Q1 of 2027 after a favorable advisory committee vote. Third-quarter revenue was $37.5 million, test volumes increased 24%, and full-year Gallery sales growth guidance was updated to 17% to 21%.
GRAIL reported an FDA advisory committee vote favoring Galleri approval and anticipates a decision by early Q1 2027. Third-quarter Galleri revenue grew 14% to $37.3 million, while net loss widened to $103.6 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026TL;DR. Galleri received favorable FDA Advisory Committee support, delivered strong clinical detection results, and continued growing test volume and revenue, while GRAIL ended Q3 with $788.7 million in cash and runway into 2029. Financial pressure remains elevated, with Q3 losses, weaker adjusted gross margin, lower ASPs, a returning Illumina royalty, competitive headwinds, and no combined reduction in Stage III and IV cancers.
- + The FDA Advisory Committee voted in favor of Galleri approval, with a decision expected by early Q1 2027.
- + The NHS-Galleri and PATHFINDER 2 studies demonstrated substantially increased cancer detection with robust performance and a favorable safety profile.
- + The NHS-Galleri trial reported more than a 20% reduction in Stage IV diagnoses across 12 prespecified aggressive cancers and a 25% reduction in cancers diagnosed after emergency presentation.
- + Q3 Galleri test volume increased approximately 24% year-over-year to more than 56,000 tests.
- + Galleri revenue grew 14% year-over-year to $37.3 million in Q3.
- + GRAIL ended Q3 with $788.7 million in cash and expects that balance to provide runway into 2029.
- − Q3 produced a $103.6 million net loss, an $18.1 million gross loss and a $92.6 million adjusted EBITDA loss.
- − Adjusted gross margin fell to 42% in Q3 from 55% a year earlier.
- − Promotional pricing reduced Q3 ASP to approximately $660 per test as GRAIL prioritized growth and penetration over margin optimization.
- − The suspended Illumina royalty is scheduled to resume in late December 2026 and will fully pressure first-quarter 2027 gross margin; it would have been $2.6 million in Q3.
- − Negative marketplace headlines and an active competitive environment tempered Q3 growth.
- − The NHS Gallery trial did not observe a combined reduction in Stage III and IV cancers.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Galleri test revenue | $37.27M | FY2026 Q3 | +13.6% |
|
|
|||
| Adjusted EBITDA non-GAAP | -170.19M | Six Months Ended June 30, 2026 | — |
| Adjusted Gross Profit non-GAAP | 41.25M | Six Months Ended June 30, 2026 | — |
| Galleri test volume | 61,000 | second quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GRAL
this stock
GRAIL, Inc.
|
$4.59B | +19.3% | +17.2% | — | 17.8% |
|
TMO
Thermo Fisher Scientific Inc.
|
$256.67B | +19.6% | +14.5% | 36.5 | 1.3% |
|
DHR
Danaher Corp
|
$160.81B | -0.1% | +8.5% | 37.4 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$55.03B | +3.2% | +10.4% | 47.1 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$49.99B | +30.3% | +6.4% | 34.9 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 17
GRAIL’s Galleri received favorable FDA advisory committee support: unanimous on safety, six to four on effectiveness and seven to two with one abstention on benefits outweighing risks. GRAIL expects an FDA decision by early first quarter of 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GRAL | -18.7% | -23.0% | +38.1% | -28.8% | +19.3% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -14.8% | -17.5% | +41.6% | -25.4% | +12.2% |